Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia

Kennedy, J. S.; Deberdt, Walter; Siegal, Alan P.; Micca, Joseph L.; Degenhardt, Elisabeth K.; Ahl, Jonna; Meyers, Adam L.; Kaiser, Christopher J.; Baker, Robert W.

doi:10.1002/gps.1397

Cited by 33 publications

(37 citation statements)

References 19 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results of the overall treatment comparisons in the present study differ from findings in a study of Alzheimer's dementia patients without BPSD in which olanzapine-treated patients with moderately severe baseline cognitive impairment experienced significant cognitive decline (Kennedy et al, 2005). The reason for differences in cognitive vulnerability between dementia patients with BPSD and those without BPSD during olanzapine treatment is not readily apparent.…”

Section: Discussioncontrasting

confidence: 60%

“…In one of these trials, significant cognitive improvement was reported in patients who received olanzapine 2.5 mg/d (De Deyn et al, 2004). The potential to improve cognition was explored further in a trial in dementia patients without BPSD (Kennedy et al, 2005). In that study, patients who received olanzapine experienced a significant decline in cognition, which was greatest in those with more severe cognitive impairment at baseline.…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post‐hoc analysis

Deberdt¹,

Siegal

Ahl

et al. 2007

Int J Geriat Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 60%

Section: Introductionmentioning

confidence: 96%

Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post‐hoc analysis

Deberdt¹,

Siegal

Ahl

et al. 2007

Int J Geriat Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

“…10 Studies of the atypical olanzapine have reported mixed results, ranging from no effect 11 to enhancing 12 or worsening cognition. 13 RCTs using risperidone for neuropsychiatric symptoms in dementia have, however, consistently found it to be effective without cognitive side effects. [14][15][16] Two recent systematic reviews report only a modest improvement in neuropsychiatric symptoms from atypicals 17 and none from typical antipsychotics.…”

mentioning

confidence: 99%

Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study

Livingston

Walker

Cooper

2007

Journal of Neurology, Neurosurgery & Psychiatry

View full text Add to dashboard Cite

Objective: To investigate in a longitudinal cohort of people with Alzheimer's disease whether taking antipsychotics is associated with more rapid cognitive deterioration. Method: From a sample of 224 people with Alzheimer's disease recruited as epidemiologically representative, those taking antipsychotic drugs for more than 6 months were compared with those who were not, in terms of change in three measures of cognition. The effects of potential mediators and confounders (demographic factors, neuropsychiatric symptoms, cognitive severity and cholinesterase inhibitors) were also examined. Results: No significant difference was observed in cognitive decline between those taking antipsychotics (atypical or any) and others on any measure of cognition. The only predictor of more cognitive decline was greater baseline cognitive severity (B = 3.3, 95% confidence interval 0.6 to 6

show abstract

“…It has been hypothesized in the past that olanzapine may benefit cognition through antagonism of cholinergic neuron receptors M2, 5HT3, and 5HT6. Multiple short-term clinical trials in AD have shown a worsening of cognition when treated with atypical antipsychotics [125,126]. …”

Section: Resultsmentioning

confidence: 99%

A Review: Treatment of Alzheimer’s Disease Discovered in Repurposed Agents

Appleby¹,

Nacopoulos²,

Milano³

et al. 2013

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Background/Aims: Many compounds that have already been approved for alternate diagnoses have been studied in relation to Alzheimer’s disease (AD). The purpose of this review is to summarize these studies and discuss the rationale and benefits of repurposing drugs for AD treatment. Methods: Studies of drugs related to AD treatment that were relevant to a disease-modifying mechanism of action (MOA) and are already approved by the Food and Drug Administration for non-AD diagnoses were collected from PubMed. Results: Many drugs already approved for the treatment of other diseases have been studied in relation to AD treatment. Numerous drugs with known toxicity profiles have the potential to be repurposed as a treatment for AD. Conclusion: Known MOA, toxicology, and pharmacodynamic profiles would accelerate the process and increase the odds of finding a more timely disease-modifying treatment for AD.

show abstract

Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia

Abstract: In this 26-week study non-psychotic/non-agitated patients with Alzheimer's disease treated with olanzapine experienced significant worsening of cognition as compared to placebo.

Cited by 33 publications

References 19 publications

Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post‐hoc analysis

Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post‐hoc analysis

Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study

A Review: Treatment of Alzheimer’s Disease Discovered in Repurposed Agents

Contact Info

Product

Resources

About